New book by Larry Connors Click here Improve your trading - See how
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. Its endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of hyperphosphatemia in patients with end-stage renal disease. The company's oncology products include KRX-0401, a Phase II clinical stage product for the treatment of renal cancer and other multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. It also develops neurology products, including KRX-0701, a Phase II clinical stage product for the treatment of diabetic neuropathy; and KRX-0501, a Phase I clinical stage product for the treatment of neurological disorders. Keryx Biopharmaceuticals, Inc. has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; Opocrin, S.p.A.; AEterna Zentaris, Inc.; The National Institutes of Health; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; AusAm Biotechnologies, Inc.; Degussa AG; Japan Tobacco, Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Further, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals, Inc. is based in New York, New York. With 43.7 million shares outstanding and 5.71 million shares declared short as of May 2008, there is a failure to deliver in shares of KERX. According to quarterly data provided by the SEC, there were still 16,868 shares of KERX that were failing-to-deliver as of September 28, 2007.
Micromet Inc. (NASDAQ: MITI | Quote | Chart | News | PowerRating) a biopharmaceutical company, develops antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Its products under preclinical development include MT103 that is developed using BiTE antibody technology platform, which is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase I clinical trial for the treatment of patients with non-Hodgkin's lymphoma; adecatumumab, a clinical stage human monoclonal antibody, which targets epithelial cell adhesion molecule expressing solid tumors; and MT293, a phase I clinical trial product for the treatment of patients with cancer. The company is also developing adecatumumab in a phase Ib clinical trial, evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Its products also include MT110, a BiTE antibody for EpCAM-expressing tumors; MT111, a preclinical stage product for the carcinoembryonic antigen, which is expressed in various tumors, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; EphA2 BiTE antibody, which is in preclinical stage for the treatment of cancers; MCSP BiTE antibody, a preclinical product for the treatment of melanoma; MT293, a Phase I clinical trial product for the treatment of solid tumors; MT228, a preclinical product for melanoma; and MT203 and MT204, which are in preclinical stage for inflammatory diseases. Micromet has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab. The company is headquartered in Bethesda, Maryland. With 40.78 million shares outstanding and 455,300 shares declared short as of May 2008, there is a failure to deliver in shares of MITI. According to quarterly data provided by the SEC, there were still 14,512 shares of MITI that were failing-to-deliver as of September 28, 2007.
Open Text Corp. (NASDAQ: OTEX | Quote | Chart | News | PowerRating) develops, markets, sells, and supports Enterprise Content Management (ECM) solutions. The company's ECM solutions help customers manage critical business content, as well as assist companies with the management of their content revisions, approvals to archiving, and compliance with regulatory requirements. Its principal product, Livelink, enables corporations to manage traditional forms of content, such as images, office documents, graphics, and drawings, as well as to manage electronic content, including Web pages, email, and video. The company's solutions allow users to access, view, and manage information related to a transaction or business process, without switching from one application to another. It offers solutions for compliance and governance, email management, corporate services, information systems and technology, and manufacturing and operations. Open Text Corporation provides its solutions to various industries, including government, legal, pharmaceutical and life sciences, financial services, energy, media, and manufacturing and production. The company also offers customer support, consulting, and training and integration services. It markets and licenses its products and services primarily in North America and Europe. The company has strategic alliances with Microsoft Corporation, Oracle Corporation, and SAP AG. Open Text Corporation was founded in 1991 and is headquartered in Waterloo, Canada. With 51.1 million shares outstanding and 17.71 million shares declared short as of May 2008, there is a failure to deliver in shares of OTEX. According to quarterly data provided by the SEC, there were still 160,409 shares of OTEX that were failing-to-deliver as of September 28, 2007.
ShengdaTech Inc. (NASDAQ: SDTH | Quote | Chart | News | PowerRating) engages in developing, manufacturing, and marketing nano precipitated calcium carbonate (NPCC) products. Its NPCC products are used in paper, paints, rubber, plastic, tire, and polyvinyl chloride building materials industries. The company also offers coal based chemicals, including ammonium bicarbonate used in nitrogenous fertilizers; liquid ammonia; methanol, which is used in chemical, pharmaceutical, light, and textile industries, as well as an alternative to fossil fuel; and melamine, an intermediate product of resin. Its coal based chemicals are also used as raw materials for the production of organic and inorganic chemical products, including formaldehyde and pesticides. Shengdatech, Inc. offers its products to the manufacturers and distributors of agrochemicals primarily in Shandong and other parts of northern China. The company was founded in 2005 and is based in Tai'an City, China. With 54.2 million shares outstanding and 3.23 million shares declared short as of May 2008, there is a failure to deliver in shares of SDTH. According to quarterly data provided by the SEC, there were still 110,805 shares of SDTH that were failing-to-deliver as of September 28, 2007.
Savient Pharmaceuticals Inc (NASDAQ: SVNT | Quote | Chart | News | PowerRating) a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, which are used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharmaceuticals, Inc. The company is also developing Puricase, a Phase III clinical trial product for the control of uric acid in patients with gout. It distributes its products through wholesalers. The company was founded in 1980 and is headquartered in East Brunswick, New Jersey. With 54.23 million shares outstanding and 16.94 million shares declared short as of May 2008, there is a failure to deliver in shares of SVNT. According to quarterly data provided by the SEC, there were still 11,602 shares of SVNT that were failing-to-deliver as of September 26, 2007.
International Building Technologies Group Inc. (OTCBB: INBG | Quote | Chart | News | PowerRating) engages in the manufacture and sale of building panels used in construction worldwide. It also provides site planning, architectural and engineering services, contractor services, materials, equipment, training, and supervision. The company is based in Alameda, California. With 113.09 million shares outstanding and 345,400 shares declared short as of May 2008, there is a failure to deliver in shares of INBG.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,050,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk, CEO www.buyins.net Tom@buyins.net +1-800-715-9999
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
